07:34 AM EST, 12/03/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Tuesday said that the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study after reviewing initial safety data.

Enrollment in the cohort will resume pending final approval from the Paul Ehrlich Institute, Germany's medical regulatory body. Additional updates are expected in 2025, with safety data anticipated in the first half and initial efficacy results in the second half.

The GOBLET study is evaluating treatments across multiple gastrointestinal cancers. In cohort 5, the study is assessing Oncolytics' pelareorep combined with modified Folfirinox, with or without atezolizumab in patients with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). This cohort is funded by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN).